MedWatch

Morgan Stanley: 12 new product launches will pave the way for Ambu

Ambu's many product launches provide beneficial opportunities for Ambu, according to analyst group at investment banking company Morgan Stanley.

Photo: Ambu / PR

Morgan Stanley analysts support the financial institution's positive coverage of Ambu, which was initiated with the recommendation "overweight" and a DKK 350 (USD 56.4) price target.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs